



Press Release

Synairgen plc (‘Synairgen’ or the ‘Company’)

Grant of options

Southampton, UK – 19 June 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 18 June 2020 the Board of Synairgen granted options (‘Options’) over 1,767,985 ordinary shares of one pence each in the capital of the Company (‘Ordinary Shares’) at an exercise price of one pence per Ordinary Share. The Options represent in aggregate 1.18 per cent. of the Company’s issued share capital.

The Options are issued under the Company’s existing Long Term Incentive Plan and are exercisable between 18 June 2023 and 17 June 2030, subject to achievement of performance criteria related to the increase in the total shareholder return of the Company. Following this grant, Synairgen has 10,255,500 options in issue, representing 6.86 per cent. of the Company’s issued share capital.

Included in the number of Options granted on 18 June 2020, the following Options were issued to directors:

Director	Options Issued
Richard Marsden	490,817
Dr. Phillip Monk	354,483
John Ward	381,749

Following the issue of the Options, the interests of the directors of the Company at 18 June 2020 are as follows:

Director	Total options	Ordinary shares	Total interest	Percentage holding of fully diluted share capital
Richard Marsden	3,533,839	367,825	3,901,664	2.44%
Dr. Phillip Monk	1,948,582	244,600	2,193,182	1.37%
John Ward	2,481,064	367,577	2,848,641	1.78%
Simon Shaw	-	1,531,239	1,531,239	0.96%
Iain Buchanan	212,765	112,741	325,506	0.20%
Dr. Bruce Campbell	-	322,830	322,830	0.20%
Prof. Stephen Holgate	-	886,931	886,931	0.56%

Jody Brookes and Victoria Tear, also persons disclosing managerial responsibilities, were granted 135,576 and 101,270 Options respectively.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No. 596/2014 (‘MAR’)

For further information, please contact:

Synairgen plc

Richard Marsden, Chief Executive Officer

John Ward, Finance Director

Tel: + 44 (0) 23 8051 2800

finnCap

Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

Tel: + 44 (0) 20 7220 0500

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott, Sue Stuart, Olivia Manser

synairgen@consilium-comms.com

Tel: +44 (0) 20 3709 5700

Notes for Editors**About Synairgen**

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')	
a) Name	Richard Marsden
2. Reason for notification	
a) Position / status	Chief Executive Officer
b) Initial notification / amendment	Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	Synairgen plc
b) LEI	213800IMMTOPPDF8HD24
4. Details of the transaction(s):	
a) Description of the financial instrument	Options over ordinary shares of 1p each
Identification code	GB00B0381Z20
b) Nature of the transaction	Award of Options under the Synairgen LTIP
c) Price(s) and volume(s)	490,817 Options awarded
d) Aggregated information	n/a
Aggregated volume Price	

e) Date of the transaction	18 June 2020
f) Place of the transaction	Outside a trading venue

1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')	
a) Name	Dr Phillip Monk
2. Reason for notification	
a) Position / status	Chief Scientific Officer
b) Initial notification / amendment	Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	Synairgen plc
b) LEI	213800IMMTOPPDF8HD24
4. Details of the transaction(s):	
a) Description of the financial instrument	Options over ordinary shares of 1p each
Identification code	GB00B0381Z20
b) Nature of the transaction	Award of Options under the Synairgen LTIP
c) Price(s) and volume(s)	354,483 Options awarded
d) Aggregated information	n/a
Aggregated volume Price	
e) Date of the transaction	18 June 2020
f) Place of the transaction	Outside a trading venue

1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')	
a) Name	John Ward
2. Reason for notification	
a) Position / status	Finance Director
b) Initial notification / amendment	Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	Synairgen plc
b) LEI	213800IMMTOPPDF8HD24
4. Details of the transaction(s):	
a) Description of the financial instrument	Options over ordinary shares of 1p each
Identification code	GB00B0381Z20
b) Nature of the transaction	Award of Options under the Synairgen LTIP
c) Price(s) and volume(s)	381,749 Options awarded

d) Aggregated information	n/a
Aggregated volume Price	
e) Date of the transaction	18 June 2020
f) Place of the transaction	Outside a trading venue

1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')	
a) Name	Jody Brookes
2. Reason for notification	
a) Position / status	Head of Clinical Operations
b) Initial notification / amendment	Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	Synairgen plc
b) LEI	213800IMMTOPPDF8HD24
4. Details of the transaction(s):	
a) Description of the financial instrument	Options over ordinary shares of 1p each
Identification code	GB00B0381Z20
b) Nature of the transaction	Award of Options under the Synairgen LTIP
c) Price(s) and volume(s)	135,576 Options awarded
d) Aggregated information	n/a
Aggregated volume Price	
e) Date of the transaction	18 June 2020
f) Place of the transaction	Outside a trading venue

1. Details of Persons Discharging Managerial Responsibilities ('PDMR') / person closely associated with them ('PCA')	
a) Name	Victoria Tear
2. Reason for notification	
a) Position / status	Head of Laboratories
b) Initial notification / amendment	Initial Notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	Synairgen plc
b) LEI	213800IMMTOPPDF8HD24
4. Details of the transaction(s):	
a) Description of the financial instrument	Options over ordinary shares of 1p each
Identification code	GB00B0381Z20
b) Nature of the transaction	Award of Options under the Synairgen LTIP
c) Price(s) and volume(s)	101,270 Options awarded

d) Aggregated information	n/a
Aggregated volume Price	
e) Date of the transaction	18 June 2020
f) Place of the transaction	Outside a trading venue